<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2474-2-1.anc" start="10332" end="10337" sStart="10173" offset="159" sid="r7.1.use.v.0491" wn="1" wnkey="use%2:34:01::" annotator="brubin" text="The insertion/deletion genotype of subjects was performed using purified genomic DNA (prepared as above) and the polymerase chain reaction using the forward primer 5'CTGGAGACCACTCCCATCCTTTCT3' and the reverse primer 5'GATGTGGCCATCACATTCGTCAGAT3' as per Rigat et al [ 13]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2474-2-1.anc" start="12120" end="12125" sStart="null" offset="0" sid="null" wn="6" wnkey="power%1:10:00::" annotator="veweser" text="Assuming an unmatched case control design with alpha = 0.05 and beta = 0.80, post-hoc &lt;b&gt;power&lt;/b&gt; analysis was performed to determine the minimum detectable relative risk detectable with the given sample size [ 24]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2474-2-1.anc" start="12120" end="12125" sStart="null" offset="0" sid="null" wn="2" wnkey="power%1:19:00::" annotator="tofox" text="Assuming an unmatched case control design with alpha = 0.05 and beta = 0.80, post-hoc &lt;b&gt;power&lt;/b&gt; analysis was performed to determine the minimum detectable relative risk detectable with the given sample size [ 24]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2474-2-1.anc" start="13686" end="13692" sStart="null" offset="55" sid="r8.number.n.0776" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="Post-hoc power analysis revealed that with the number of subjects available, the minimum detectable risk for the deletion-deletion polymorphism of the ACE gene being associated with a higher risk of thromboembolic complications was 2.7." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2474-2-1.anc" start="1372" end="1377" sStart="null" offset="0" sid="null" wn="3" wnkey="know%2:31:02::" annotator="carichter" text="Until recently, the only &lt;b&gt;known&lt;/b&gt; hypercoagulable states were several rare genetic disorders of the coagulation cascade (antithrombin III, protein C, and protein S deficiency), which accounted for only a small percentage of all patients with venous thrombosis [ 16]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2474-2-1.anc" start="1941" end="1949" sStart="null" offset="107" sid="r11.function.n.0359" wn="2" wnkey="function%1:07:00::" annotator="anfahmy" text="Further investigation revealed an autosomal-dominant inherited defect in the anticoagulant function of factor V resulting in resistance to the anticoagulant action of activated protein C (APC) [ 18]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2474-2-1.anc" start="18385" end="18389" sStart="null" offset="2" sid="r9.fold.v.0850" wn="" wnkey="null" annotator="anfahmy" text="9 fold increased risk for the factor V Leiden mutation and a 2.7 fold increased risk for the deletion/deletion polymorphism of the angiotensin converting enzyme gene) would have been required to detect a significant difference between the prevalence of these mutations in our case and control groups." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2474-2-1.anc" start="18456" end="18460" sStart="null" offset="73" sid="r9.fold.v.0398" wn="" wnkey="null" annotator="anfahmy" text="9 fold increased risk for the factor V Leiden mutation and a 2.7 fold increased risk for the deletion/deletion polymorphism of the angiotensin converting enzyme gene) would have been required to detect a significant difference between the prevalence of these mutations in our case and control groups." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2474-2-1.anc" start="14162" end="14167" sStart="null" offset="6" sid="r10.find.v.0819" wn="4" wnkey="find%2:32:00::" annotator="cgozo" text="[ 19] found that the Factor V Leiden mutation was associated with an increased risk of deep venous thrombosis (as determined by routine bilateral ascending venography) in 480 European patients who had undergone total hip arthroplasty, however only 41 of the 120 patients with deep venous thrombosis had proximal thrombi." />
  </sentences>
</list>